Cohen, Stanley B
Tanaka, Yoshiya
Mariette, Xavier
Curtis, Jeffrey R
Lee, Eun Bong
Nash, Peter
Winthrop, Kevin L
Charles-Schoeman, Christina
Thirunavukkarasu, Krishan
DeMasi, Ryan
Geier, Jamie
Kwok, Kenneth
Wang, Lisy
Riese, Richard
Wollenhaupt, Jürgen
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials (Results)
https://doi.org/10.1136/annrheumdis-2016-210457
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
This article is maintained by: Elsevier
Article Title: Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2016-210457
Content Type: article
Copyright: Copyright © 2017 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.